Human PARK7 Antibody Pair - BSA and Azide free (DJ1) (ab241845)
Key features and details
- Unconjugated capture and detector antibodies
- Adaptable to any antibody pair-based assay format
- Antibody concentration ~ 1 mg/ml
- BSA and azide free buffer - ready for conjugation
- Reacts with: Human
Overview
-
Product name
Human PARK7 Antibody Pair - BSA and Azide free (DJ1)
See all PARK7/DJ1 kits -
Assay type
ELISA set -
Range
312.5 pg/ml - 20000 pg/ml -
Species reactivity
Reacts with: Human -
Product overview
The Antibody Pair can be used to quantify Human PARK7. BSA and Azide free antibody pairs include unconjugated capture and detector antibodies suitable for sandwich ELISAs. The antibodies are provided at an approximate concentration of 1 mg/ml as measured by the protein A280 method. The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Both capture and detector antibodies are rabbit monoclonal antibodies delivering consistent, specific, and sensitive results.
For additional information on the performance of the antibody pair, see the equivalent SimpleStep ELISA® Kit (ab215535), which uses the same antibodies. However, due to differences in their formulation, this antibody pair cannot be used with the consumables provided with our SimpleStep ELISA Kits. Please note that the range provided for the pairs is only an estimation based on the performance of the related product using the same antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody pair in your assay.
Download SDS here.
-
Tested applications
Suitable for: Sandwich ELISAmore details -
Platform
Reagents
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Carrier free
Yes -
Components 10 x 96 tests Human PARK7 Capture Antibody (unconjugated) 1 x 100µg Human PARK7 Detector Antibody (unconjugated) 1 x 100µg -
Research areas
-
Function
Protects cells against oxidative stress and cell death. Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death. May act as an atypical peroxiredoxin-like peroxidase that scavenges hydrogen peroxide. Following removal of a C-terminal peptide, displays protease activity and enhanced cytoprotective action against oxidative stress-induced apoptosis. Stabilizes NFE2L2 by preventing its association with KEAP1 and its subsequent ubiquitination. Binds to OTUD7B and inhibits its deubiquitinating activity. Enhances RELA nuclear translocation. Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress. Required for correct mitochondrial morphology and function and for autophagy of dysfunctional mitochondria. Regulates astrocyte inflammatory responses. Acts as a positive regulator of androgen receptor-dependent transcription. Prevents aggregation of SNCA. Plays a role in fertilization. Has no proteolytic activity. Has cell-growth promoting activity and transforming activity. May function as a redox-sensitive chaperone. -
Tissue specificity
Highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart. Detected at slightly lower levels in placenta and brain. Detected in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa. -
Involvement in disease
Defects in PARK7 are the cause of Parkinson disease type 7 (PARK7) [MIM:606324]. A neurodegenerative disorder characterized by resting tremor, postural tremor, bradykinesia, muscular rigidity, anxiety and psychotic episodes. PARK7 has onset before 40 years, slow progression and initial good response to levodopa. Some patients may show traits reminiscent of amyotrophic lateral sclerosis-parkinsonism/dementia complex (Guam disease). -
Sequence similarities
Belongs to the peptidase C56 family. -
Post-translational
modificationsSumoylated on Lys-130 by PIAS2 or PIAS4; which is enhanced after ultraviolet irradiation and essential for cell-growth promoting activity and transforming activity.
Cys-106 is easily oxidized to sulfinic acid.
Undergoes cleavage of a C-terminal peptide and subsequent activation of protease activity in response to oxidative stress. -
Cellular localization
Cytoplasm. Nucleus. Mitochondrion. Under normal conditions, located predominantly in the cytoplasm and, to a lesser extent, in the nucleus and mitochondrion. Translocates to the mitochondrion and subsequently to the nucleus in response to oxidative stress and exerts an increased cytoprotective effect against oxidative damage. Detected in tau inclusions in brains from neurodegenerative disease patients. - Information by UniProt
-
Alternative names
- CAP1
- DJ-1
- DJ1
see all -
Database links
- Entrez Gene: 11315 Human
- Omim: 602533 Human
- SwissProt: Q99497 Human
- Unigene: 419640 Human
Images
-
Sandwich ELISA - Human PARK7 Antibody Pair - BSA and Azide free (DJ1) (ab241845)To learn more about the advantages of recombinant antibodies see here.
